Results of a clinical study indicate that Allergan Inc.’s topical cyclosporine proves beneficial in various forms of the dry eye disease. The drug was found to stop the progress of the disease in some patients and cure symptoms in others. The condition of 72.1% of patients improved to a great extent. Greater efficacy of the medication in the mild group indicates that early treatment of the disease may give better results. The study was supported by Allergan Inc.